SAGE-718 on FDA Fast Track as Potential Huntington’s Therapy

SAGE-718 on FDA Fast Track as Potential Huntington’s Therapy

306681

SAGE-718 on FDA Fast Track as Potential Huntington’s Therapy

The U.S. Food and Drug Administration (FDA) has granted fast track designation to SAGE-718 as a potential therapy for Huntington’s disease. The FDA gives this designation to experimental medications with the potential to improve medical care for serious health conditions and fill unmet needs. The designation gives the therapy’s developer — Sage Therapeutics — access to more frequent meetings with the FDA to review the development plan for the medicine, with the goal of getting…

You must be logged in to read/download the full post.